Author:
Ando Takashi,Nishiyama Tsutomu,Takizawa Itsuhiro,Ishizaki Fumio,Miyashiro Yoshimichi,Takeda Keisuke,Hara Noboru,Tomita Yoshihiko
Abstract
AbstractIntratumoural dihydrotestosterone (DHT) synthesis could be an explanation for castration resistance in prostate cancer (PC). By using liquid chromatography-mass spectrometry, we evaluated the intratumoral DHT synthesis from 5α-androstane-3β,17β-diol (3β-diol), which is inactive androgen metabolized from DHT. 3β-diol had biochemical potential to be converted to DHT via three metabolic pathways and could stimulate PC cell growth. Especially, 3β-diol was not only converted back to upstream androgens such as dehydroepiandrosterone (DHEA) or Δ5-androstenediol but also converted directly to DHT which is the main pathway from 3β-diol to DHT. Abiraterone had a significant influence on the metabolism of DHEA, epiandrosterone and 3β-diol, by the inhibition of the intratumoural 3β-hydroxysteroid dehydrogenase (3β-HSD) activities which is one of key catalysts in androgen metabolic pathway. The direct-conversion of 3β-diol to DHT was catalysed by 3β-HSD and abiraterone could inhibit this activity of 3β-HSD. These results suggest that PC had a mechanism of intratumoural androgen metabolism to return inactive androgen to active androgen and intratumoural DHT synthesis from 3β-diol is important as one of the mechanisms of castration resistance in PC. Additionally, the inhibition of intratumoural 3β-HSD activity could be a new approach to castration-resistant prostate cancer treatment.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Naito, S. et al. Updated Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int. J. Urol. 17, 830–838 (2010).
2. Matsuda, T. et al. Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 40, 1192–1200 (2010).
3. Huggins, C. & Hodges, C. V. Studies on prostatic cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).
4. Oh, W. K. & Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 160, 1220–1229 (1998).
5. Page, S. T. et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab. 91, 3850–3856 (2006).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献